ETON
Eton Pharmaceuticals Inc.
$18.01
-$0.24(-1.32%)
25
Overall
20
Value
30
Tech
--
Quality
Market Cap
$498.81M
Volume
161.10K
52W Range
$8.24 - $23.00
Target Price
$29.67
Order:
Income Statement
| Metric | Trend | Chart | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Total Revenue | -- | $959.0K | $325.0K | $21.8M | $21.3M | $31.6M | $39.0M | ||
| Total Revenue | -- | $959.0K | $39.0K | $21.8M | $21.3M | $31.6M | $39.0M | ||
| COST OF GOODS SOLD | |||||||||
| Cost of Revenue | -- | $453.0K | $436.0K | $2.8M | $6.9M | $10.6M | $15.6M | ||
| GROSS PROFIT | |||||||||
| Gross Profit | -- | $506.0K | $-397.0K | $19.0M | $14.3M | $21.1M | $23.4M | ||
| OPERATING EXPENSES | |||||||||
| Operating Expenses | $10.3M | $19.1M | $26.9M | $20.5M | $22.6M | $22.3M | $26.0M | ||
| Research & Development | $5.6M | $11.6M | $14.1M | $6.2M | $4.0M | $3.3M | $3.3M | ||
| Research Expense | $5.6M | $11.6M | $14.1M | $6.2M | $4.0M | $3.3M | $3.3M | ||
| Selling, General & Administrative | $4.7M | $7.6M | $12.8M | $14.3M | $18.6M | $18.9M | $22.8M | ||
| General & Administrative Expenses | $4.7M | $7.6M | $12.8M | $14.3M | $18.6M | $18.9M | $22.8M | ||
| Salaries & Wages | $-1.9M | $1.9M | $2.6M | $3.4M | $4.2M | $3.1M | $3.2M | ||
| Depreciation & Amortization | $-63.0K | $447.0K | $347.0K | $155.0K | $66.0K | $44.0K | $50.0K | ||
| Depreciation & Amortization | $-63.0K | $447.0K | $347.0K | $155.0K | $66.0K | $44.0K | $50.0K | ||
| Amortization | -- | $41.0K | $279.0K | $352.0K | $1.7M | $907.0K | $4.7M | ||
| Other Operating Expenses | $-10.3M | $140.0K | $139.0K | $113.0K | $86.0K | $77.0K | $-139.0K | ||
| OPERATING INCOME | |||||||||
| Operating income | $-10.3M | $-18.6M | $-27.1M | $-1.5M | $-8.3M | $-1.2M | $-2.6M | ||
| EBITDA | $-12.7M | $-17.8M | $-26.5M | $157.0K | $-6.2M | $1.5M | $522.0K | ||
| NON-OPERATING ITEMS | |||||||||
| Interest Expense (Non-Operating) | -- | $98.0K | $884.0K | $1.0M | $955.0K | $1.1M | $2.0M | ||
| Intinc | $164.0K | $82.0K | $48.0K | $134.0K | $231.0K | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $164.0K | $-16.0K | $-836.0K | $-908.0K | $761.0K | $-1.1M | $-2.0M | ||
| Other Income/Expense | $2.6M | $-281.0K | $859.0K | $460.0K | $761.0K | $-503.0K | $1.2M | ||
| Other Special Charges | $-2.6M | $281.0K | $-859.0K | $-641.0K | $-761.0K | $503.0K | $-1.2M | ||
| PRE-TAX INCOME | |||||||||
| EBIT | $-12.7M | $-18.2M | $-27.1M | $-453.0K | $-8.1M | $371.0K | $-1.8M | ||
| Pre-Tax Income | $-12.7M | $-18.3M | $-28.0M | $-2.0M | $-9.0M | $-689.0K | $-3.8M | ||
| INCOME TAX | |||||||||
| Tax Provision | $-1.9M | $4.0M | $6.0M | $460.0K | $2.3M | $247.0K | $15.0K | ||
| NET INCOME | |||||||||
| Net Income | $-12.7M | $-18.3M | $-28.0M | $-2.0M | $-9.0M | $-936.0K | $-3.8M | ||
| Net Income (Continuing Operations) | $-12.7M | $-18.3M | $-28.0M | $-2.0M | $-9.0M | $-936.0K | $-3.8M | ||
| Net Income (Discontinued Operations) | $-12.7M | $-18.3M | $-28.0M | $-2.0M | $-9.0M | $-936.0K | $-3.8M | ||
| Net Income (Common Stockholders) | $6.3M | $-18.3M | $-27.4M | $-2.0M | $-9.0M | $-936.0K | $-3.8M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-3.8M | ||
| TOTALS | |||||||||
| Total Expenses | $10.3M | $19.6M | $26.9M | $23.3M | $29.5M | $32.8M | $41.6M | ||
| SHARE & EPS DATA | |||||||||
| Average Shares Outstanding | $6.4M | $17.8M | $21.0M | $25.2M | $25.1M | $25.6M | $25.9M | ||
| Average Shares Outstanding (Diluted) | $6.4M | $17.8M | $21.0M | $25.2M | $25.1M | $25.6M | $25.9M | ||
| Shares Outstanding | $17.6M | $17.9M | $24.4M | $24.6M | $25.5M | $25.7M | $26.8M | ||
| Basic EPS | -- | $-1.03 | $-1.33 | $-0.08 | $-0.36 | $-0.04 | $-0.15 | ||
| Basic EPS (Continuing Operations) | -- | $-1.03 | $-1.33 | $-0.08 | $-0.36 | $-0.04 | $-0.15 | ||
| Diluted EPS | $-5.8 | $-1.03 | $-1.33 | $-0.08 | $-0.36 | $-0.04 | $-0.15 | ||
| Diluted EPS (Continuing Operations) | $-5.8 | -- | -- | -- | -- | -- | -- | ||
| OTHER METRICS | |||||||||
| Accretion On Preferred Stock | $-2.5M | -- | -- | -- | -- | -- | -- | ||
| Accrued Preferred Stock Dividends | $-19.0M | -- | -- | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | -- | $181.0K | -- | -- | -- | ||
| Other Gand A | $4.7M | $7.6M | $12.8M | $14.3M | $18.6M | $18.9M | $22.8M | ||
| Otherunder Preferred Stock Dividend | $-19.0M | -- | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | $-19.0M | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $-115.0K | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ETON | $18.01 | -1.3% | 161.10K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Eton Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW